Gharbharan A, Jordans CC, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FP, Stalenhoef-Schukken JE, Dofferhoff A, Ludwig I, Koster A. Results of potent neutralizing antibodies from convalescent plasma in sufferers hospitalized for extreme SARS-CoV-2 an infection. Nat Commun. 2021;12:3189.
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L. Therapy of 5 critically ailing sufferers with COVID-19 with convalescent plasma. JAMA. 2020;323:1582–9.
Ganesh R, Philpot LM, Bierle DM, Anderson RJ, Arndt LL, Arndt RF, Culbertson TL, DestroBorgen MJ, Hanson SN, Kennedy BD. Actual-world medical outcomes of bamlanivimab and casirivimab-imdevimab amongst high-risk sufferers with delicate to average coronavirus illness 2019. J Infect Dis. 2021;224:1278–86.
Al-Obaidi MM, Gungor AB, Nematollahi S, Zangeneh TT, Bedrick EJ, Johnson KM, Low-Adegbija NE, Alam R, Rangan P, WilliamHeise C. Effectiveness of casirivimab-imdevimab monoclonal antibody remedy amongst high-risk sufferers with extreme acute respiratory syndrome coronavirus 2 B. 1.617.2 (Delta variant) an infection. Open Discussion board Infect Dis. 2022. https://doi.org/10.1093/ofid/ofac186.
Lv Z, Deng Y-Q, Ye Q, Cao L, Solar C-Y, Fan C, Huang W, Solar S, Solar Y, Zhu L. Structural foundation for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369:1505–9.
Cao Y, Yisimayi A, Jian F, Track W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Solar H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Track X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron an infection. Nature. 2022;608:593–602.
Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, Li M, Cui Y, Chen Y, Qiao R, Li L, Yang L, Li Y, Hu Z, Zhang W, Wang P. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. 2022;30:1077-1083.e4.
Cao Y, Track W, Wang L, Liu P, Yue C, Jian F, Yu Y, Yisimayi A, Wang P, Wang Y, Zhu Q, Deng J, Fu W, Yu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Yang S, Niu X, Gu Q, Shao F, Hao X, Meng B, Gupta RK, Jin R, Wang Y, Xie XS, Wang X. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron an infection. Cell Host Microbe. 2022;30:1527-1539.e5.
Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z, Ho DD. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553–6.
Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L, Ho DD. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279-286.e8.
Yue C, Track W, Wang L, Jian F, Chen X, Gao F, Shen Z, Wang Y, Wang X, Cao Y. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis. 2023;23:278–80.
Rockett R, Basile Okay, Maddocks S, Fong W, Agius JE, Johnson-Mackinnon J, Arnott A, Chandra S, Gall M, Draper J. Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use. N Engl J Med. 2022;386:1477–9.
Yoo SH, Kim L, Lu M, Nagoshi Okay, Namchuk MN. A overview of medical efficacy knowledge supporting emergency use authorization for COVID-19 therapeutics and classes for future pandemics. Clin Transl Sci. 2022;15:2279–92.
Weidenbacher PA-B, Waltari E, RiosKobara de Los I, Bell BN, Morris MK, Cheng Y-C, Hanson C, Pak JE, Kim PS. Changing non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Nat Chem Biol. 2022;18:1270–6.
Desautels TA, Arrildt KT, Zemla AT, Lau EY, Zhu F, Ricci D, Cronin S, Zost SJ, Binshtein E, Scheaffer SM. Computationally restoring the efficiency of a medical antibody towards Omicron. Nature. 2024;629:1–8.
Inoue T, Yamamoto Y, Sato Okay, Okemoto-Nakamura Y, Shimizu Y, Ogawa M, Onodera T, Takahashi Y, Wakita T, Kaneko MK. Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed utilizing non-neutralizing antibodies. iScience. 2024;27:109363.
Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: latest progress and future views. Sign Transduct Goal Ther. 2022;7:1–11.
Meng B, Abdullahi A, Ferreira IA, Goonawardane N, Saito A, Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S. Altered TMPRSS2 utilization by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–14.
Zhao H, Lu L, Peng Z, Chen L-L, Meng X, Zhang C, Ip JD, Chan W-M, Chu AW-H, Chan Okay-H. SARS-CoV-2 Omicron variant reveals much less environment friendly replication and fusion exercise when put next with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022;11:277–83.
Chow MY, Pan HW, Seow HC, Lam JK. Inhalable neutralizing antibodies–promising method to combating respiratory viral infections. Traits Pharmacol Sci. 2023;44:85–97.
Li X, Peng P, Deng H, Yang Q, Chen S, Li B, He M, Jin A, Yang Z, Tang N. Actual-world effectiveness of an intranasal spray A8G6 antibody cocktail within the post-exposure prophylaxis of COVID-19. Sign Transduct Goal Ther. 2023;8:403.
Lin Y, Yue S, Yang Y, Yang S, Pan Z, Yang X, Gao L, Zhou J, Li Z, Hu L. Nasal spray of neutralizing monoclonal antibody 35B5 confers potential prophylaxis towards extreme acute respiratory syndrome coronavirus 2 variants of concern: a small-scale medical trial. Clin Infect Dis. 2023;76:e336–41.
Patel A, Rosenke Okay, Parzych EM, Feldmann F, Bharti S, Griffin AJ, Schouest B, Lewis M, Choi J, Chokkalingam N. In vivo supply of engineered artificial DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates. Emerg Microbes Infect. 2024;13:2294860.
Maisonnasse P, Aldon Y, Marc A, Marlin R, Dereuddre-Bosquet N, Kuzmina NA, Freyn AW, Snitselaar JL, Gonçalves A, Caniels TG. COVA1-18 neutralizing antibody protects towards SARS-CoV-2 in three preclinical fashions. Nat Commun. 2021;12:6097.
Lavatory Y-M, McTamney PM, Arends RH, Abram ME, Aksyuk AA, Diallo S, Flores DJ, Kelly EJ, Ren Okay, Roque R. The SARS-CoV-2 monoclonal antibody mixture, AZD7442, is protecting in nonhuman primates and has an prolonged half-life in people. Sci Transl Med. 2022;14:eabl8124.
Cobb RR, Nkolola J, Gilchuk P, Chandrashekar A, Yu J, Home RV, Earnhart CG, Dorsey NM, Hopkins SA, Snow DM. A mixture of two human neutralizing antibodies prevents SARS-CoV-2 an infection in cynomolgus macaques. Med. 2022;3:188-203.e4.
Jia J, Yin Z, Zhang X, Li H, Meng D, Liu Q, Wang H, Han M, Suo S, Liu Y. Feasibility research of nebulized SARS-CoV-2 neutralizing antibody in mice and cynomolgus monkeys. Pharm Res. 2022;39:2191–201.
Hart TK, Prepare dinner RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER. Preclinical efficacy and security of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108:250–7.
Streblow DN, Hirsch AJ, Stanton JJ, Lewis AD, Colgin L, Hessell AJ, Kreklywich CN, Smith JL, Sutton WF, Chauvin D. Aerosol supply of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology. Nat Commun. 2023;14:7062.
Cagno V, Andreozzi P, Dalicarnasso M, Jacob Silva P, Mueller M, Galloux M, Le Goffic R, Jones ST, Vallino M, Hodek J, Weber J, Sen S, Janecek ER, Bekdemir A, Sanavio B, Martinelli C, Donalisio M, Rameix Welti MA, Eleouet JF, Han Y, Kaiser L, Vukovic L, Tapparel C, Kral P, Krol S, Lembo D, Stellacci F. Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat Mater. 2018;17:195–203.
Zhang J, Xu Y, Huang Y, Wang H, Gong X, Wei Okay. Spatially patterned neutralizing icosahedral DNA nanocage for environment friendly SARS-CoV-2 blocking. J Am Chem Soc. 2022;144:13146–53.
Gao R, Xu X, Kumar P, Liu Y, Zhang H, Guo X, Solar M, Colombari FM, de Moura AF, Hao C. Tapered chiral nanoparticles as broad-spectrum thermally steady antivirals for SARS-CoV-2 variants. Proc Natl Acad Sci USA. 2024;121: e2310469121.
Kong B, Moon S, Kim Y, Heo P, Jung Y, Yu S-H, Chung J, Ban C, Kim YH, Kim P. Virucidal nano-perforator of viral membrane trapping viral RNAs within the endosome. Nat Commun. 2019;10:185.
Oh H, Jung Y, Moon S, Hwang J, Ban C, Chung J, Chung W-J, Kweon D-H. Growth of end-spliced dimeric nanodiscs for the improved virucidal exercise of a nanoperforator. ACS Appl Mater Interfaces. 2021;13:36757–68.
Moon S, Chung J, Kim Y, Hong C, Kim S, Hwang J, Jung Y, Chung W-J, Kweon D-H. Bifunctional hetero di-disc for broad-spectrum influenza neutralization. NBM. 2022;44: 102587.
Hwang J, Kim BK, Moon S, Park W, Kim KW, Yoon JH, Oh H, Jung S, Park Y, Kim S. Conversion of host cell receptor into virus destructor by immunodisc to neutralize numerous SARS-CoV-2 variants. Adv Healthc Mater. 2024;13:2470091.
Hwang J, Jung Y, Moon S, Yu S, Oh H, Kim S, Kim KW, Yoon JH, Chun J, Kim SJ. Nanodisc-mediated conversion of virustatic antiviral antibody to disrupt virus envelope in contaminated cells. Small Strategies. 2022;6:2101516.
Denisov IG, Sligar SG. Nanodiscs in membrane biochemistry and biophysics. Chem Rev. 2017;117:4669–713.
Son S, Ahn SB, Kim G, Jang Y, Ko C, Kim M, Kim SJ. Identification of broad-spectrum neutralizing antibodies towards influenza A virus and analysis of their prophylactic efficacy in mice. Antiviral Res. 2023;213: 105591.
Yoon H, Track JM, Ryu CJ, Kim Y-G, Lee EK, Kang S, Kim SJ. An environment friendly technique for cell-based antibody library choice utilizing an built-in vector system. BMC Biotechnol. 2012;12:1–10.
Barinka C, Ptacek J, Richter A, Novakova Z, Morath V, Skerra A. Choice and characterization of Anticalins focusing on human prostate-specific membrane antigen (PSMA). Protein Eng Des Sel. 2016;29:105–15.
DeLano WL, Ultsch MH, de Vos AM, Wells JA. Convergent options to binding at a protein-protein interface. Science. 2000;287:1279–83.
Ju B, Zhang Q, Ge J, Wang R, Solar J, Ge X, Yu J, Shan S, Zhou B, Track S. Human neutralizing antibodies elicited by SARS-CoV-2 an infection. Nature. 2020;584:115–9.
Nguyen L, McCord KA, Bui DT, Bouwman KM, Kitova EN, Elaish M, Kumawat D, Daskhan GC, Tomris I, Han L. Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2. Nat Chem Biol. 2022;18:81–90.
Negi G, Sharma A, Chaudhary M, Gupta D, Harshan KH, Parveen N. SARS-CoV-2 binding to terminal sialic acid of gangliosides embedded in lipid membranes. ACS Infect Dis. 2023;9:1346–61.
Dey M, Sharma A, Dhanawat G, Gupta D, Harshan KH, Parveen N. Synergistic binding of SARS-CoV-2 to ACE2 and gangliosides in native lipid membranes. ACS Infect Dis. 2024;10:907–16.
Huang Y, Yang C, Xu X-F, Xu W, Liu S-W. Structural and purposeful properties of SARS-CoV-2 spike protein: potential antivirus drug improvement for COVID-19. Acta Pharmacol Sin. 2020;41:1141–9.
ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, Preiser W, Doerr HW, Chow VT, de Kruif J, Peiris JS, Goudsmit J. Human monoclonal antibody mixture towards SARS coronavirus: synergy and protection of escape mutants. PLoS Med. 2006;3: e237.
Yuan M, Wu NC, Zhu X, Lee C-CD, So RT, Lv H, Mok CK, Wilson IA. A extremely conserved cryptic epitope within the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368:630–3.
Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza Okay, Negron N, Ni M, Wei Y, Atwal GS, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA. Antibody cocktail to SARS-CoV-2 spike protein prevents fast mutational escape seen with particular person antibodies. Science. 2020;369:1014–8.
Pinto D, Park YJ, Beltramello M, Partitions AC, Tortorici MA, Bianchi S, Jaconi S, Culap Okay, Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink Okay, Veesler D, Corti D. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290–5.
Addetia A, Piccoli L, Case JB, Park YJ, Beltramello M, Guarino B, Dang H, de Melo GD, Pinto D, Sprouse Okay, Scheaffer SM, Bassi J, Silacci-Fregni C, Muoio F, Dini M, Vincenzetti L, Acosta R, Johnson D, Subramanian S, Saliba C, Giurdanella M, Lombardo G, Leoni G, Culap Okay, McAlister C, Rajesh A, Dellota E Jr, Zhou J, Farhat N, Bohan D, Noack J, Chen A, Lempp FA, Quispe J, Kergoat L, Larrous F, Cameroni E, Whitener B, Giannini O, Cippa P, Ceschi A, Ferrari P, Franzetti-Pellanda A, Biggiogero M, Garzoni C, Zappi S, Bernasconi L, Kim MJ, Rosen LE, Schnell G, Czudnochowski N, Benigni F, Franko N, Logue JK, Yoshiyama C, Stewart C, Chu H, Bourhy H, Schmid MA, Purcell LA, Snell G, Lanzavecchia A, Diamond MS, Corti D, Veesler D. Neutralization, effector perform and immune imprinting of Omicron variants. Nature. 2023;621:592–601.
Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A. Distinct evolution of SARS-CoV-2 Omicron XBB and BA 2.86/JN 1 lineages combining elevated health and antibody evasion. Nat Commun. 2024;15:2254.
Arora P, Kempf A, Nehlmeier I, Schulz SR, Jäck H-M, Pöhlmann S, Hoffmann M. Omicron sublineage BQ 11 resistance to monoclonal antibodies. Lancet Infect Dis. 2023;23:22–3.
Wang Y, Hao A, Ji P, Ma Y, Zhang Z, Chen J, Mao Q, Xiong X, Rehati P, Wang Y. A bispecific antibody reveals broad neutralization towards SARS-CoV-2 Omicron variants XBB. 1.16, BQ. 1.1 and sarbecoviruses. Nat Commun. 2024;15:5127.
Duan Y, Gong Okay, Xu S, Wang X, Zhang L, Li J, Huang F, Zhao Y, Zhu L, Li W, Huang Y. Regulation of ldl cholesterol homeostasis in well being and ailments: from mechanisms to focused therapeutics. Sign Transduct Goal Ther. 2022;7:265.
Kuai R, Li D, Chen YE, Moon L, Schwendeman T, Parhami JJ, Knudsen KL, Helmus B, Schnitzer TW. Excessive-density lipoproteins: nature’s multifunctional nanoparticles. ACS Nano. 2016;10:3015–41.
Krause BR, Remaley AT. Reconstituted HDL for the acute remedy of acute coronary syndrome. Curr Opin Lipidol. 2013;24:480–6.
MichaelGibson C, Korjian S, Tricoci P, Brown EA, Alexander M, Hernandez AM, Abraham MT, Lytle TJ, Veledar DP, Bhatt DL. Security and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I Occasion Lowering in Ischemic Syndromes I). Circulation. 2016;134:1918–30.
Kallend DG, Reijers JAA, Bellibas SE, Bobillier A, Kempen H, Burggraaf J, Moerland M, Wijngaard PLJ. A single infusion of MDCO-216 (ApoA-1 Milano/POPC) will increase ABCA1-mediated ldl cholesterol efflux and pre-beta 1 HDL in wholesome volunteers and sufferers with steady coronary artery illness. Eur Coronary heart J Cardiovasc Pharmacother. 2016;2:23–9.
